China Conjugate Vaccine Market (2018-2023)

  • ID: 4593842
  • Report
  • Region: China
  • Netscribes (India) Pvt Ltd
1 of 4

FEATURED COMPANIES

  • Bharat Biotech
  • Biological E. Limited
  • CSL Limited
  • GlaxoSmithKline
  • Merck & Co.
  • Novartis
  • MORE
China Conjugate Vaccine Market:

Conjugate vaccine is a type of vaccine that contains bacterial capsular polysaccharide, attached to a protein to enhance immunogenicity and protect against invasive diseases. China is one of the prominent markets with a significant growth rate for conjugate vaccines.

All Expanded Program on Immunization (EPI) vaccines (including tuberculosis, polio, measles, and diphtheria-tetanus-pertussis (DTP), hepatitis A and B, meningococcal, Japanese encephalitis, rubella and mumps) in China are free and mandatory for school admissions. Immunization clinics in China also offer non-EPI vaccines to children but for a fee (and are not covered by insurance programs), including influenza, varicella, Haemophilus influenza type B (Hib), rotavirus, and pneumococcal vaccines, among others.

Market Segmentation:

By disease indication, the market is segmented into:
  • Pneumococcal
  • Haemophilus influenza type B
  • Diphtheria-tetanus-pertussis
  • Meningococcal
  • Others
By end user, the market is segmented into:
  • Paediatric
  • Adult
Key growth factors:

China is projected to be a significant market for conjugate vaccines during the forecast period. Rapidly increasing geriatric population, rise in consumer awareness, growing disposable income and healthcare expenditure, modernization of healthcare infrastructure, and a growing medical tourism industry will drive the growth of the conjugated vaccines market in China. According to the United Nations, China is ageing more rapidly than almost any country in recent history. This acts as a key driver for adult vaccines, owing to more demand by the geriatric population. Since the toll of pneumococcal disease in China is enormous, pneumococcal vaccination could improve children’s health and save lives and is therefore a prime selection for inclusion in the EPI schedule.

Threats and key players:
  • The China conjugate vaccine market is expected to have significantly high growth. China has spent tremendous resources on the elimination of measles, but such elimination efforts should be combined with other immunization initiatives, such as educating caregivers about the benefits of other vaccines. The Chinese public is receiving more information about measles than about pneumonia or meningitis. Measles vaccine is free in Shanghai, but pneumococcal vaccine requires payment, which impacts the decision of the public significantly as they are reluctant to pay and get vaccinated.
  • Major Conjugate Vaccine providers operating in the market are GlaxoSmithKline, Pfizer Inc., Merck, Novartis, Sanofi Pasteur, etc.
What’s covered in the report?

1. Overview of the China conjugate vaccine market
2. Market drivers, and challenges in the China conjugate vaccine market
3. Market trends in the China conjugate vaccine market
4. Historical, current and forecasted market size data for China based on disease indication (pneumococcal, haemophilus influenza type b, diphtheria-tetanus-pertussis, meningococcal conjugate vaccines) – by revenue and by volume
5. Historical, current and forecasted market size data for China based on end user (paediatric and adult conjugate vaccines) – by revenue and by volume
6. Analysis of the competitive landscape and profiles of major companies operating in the China market

Why buy?
  • Understand the demand for conjugate vaccines to determine the viability of the market
  • Develop strategies based on the drivers and trends for each of the segments
  • Evaluate the value chain to determine the workflow and to get an idea of the current position where you are placed
  • Recognize the key competitors of this market and respond accordingly
  • Identify the initiatives and growth strategies taken up by the major companies and decide on the direction for further growth
  • Define the competitive positioning by comparing the products and services with the key players in the market
READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Bharat Biotech
  • Biological E. Limited
  • CSL Limited
  • GlaxoSmithKline
  • Merck & Co.
  • Novartis
  • MORE
Chapter 1: Executive summary
1.1 Market scope and segmentation
1.2 Key questions answered in this study
1.3 Executive summary - I
1.4 Executive summary - II

Chapter 2: Market overview
2.1. Market definitions
2.2. China market overview – by revenue
  • China historical (2015-2017) market revenue (USD Bn)
  • China forecasted (2018-2023) market revenue (USD Bn)
2.3. China market overview – by volume
  • China historical (2015-2017) market volume (Million units)
  • China forecasted (2018-2023) market volume (Million units)
2.4. China market drivers and challenges
2.4.1. China market drivers
2.4.2. China market challenges
2.5. China market trends
2.6. Value chain

Chapter 3: China major segment overview - by disease indication
3.1. Disease indication: Pneumococcal, Hib - by revenue, by volume, CAGR
  • Overview - by disease indication
  • Market share (2015, 2018 & 2023): Pneumococcal – China (USD Bn, Million units)
  • Market share (2015, 2018 & 2023): Hib – China (USD Bn, Million units)
3.2. Disease indication: DTP, Meningococcal - by revenue, by volume, CAGR
  • Overview - by disease indication
  • Market share (2015, 2018 & 2023): DTP – China (USD Bn, Million units)
  • Market share (2015, 2018 & 2023): Meningococcal – China (USD Bn, Million units)
Chapter 4: China major segment overview - by end user
4.1. End-user: Pediatric, Adult - by revenue, by volume, by CAGR
  • Overview - by end-user
  • Market share (2015, 2018 & 2023): Paediatric – China (USD Bn, Million units)
  • Market share (2015, 2018 & 2023): Adult – China (USD Bn, Million units)
Chapter 5: Competitive landscape
5.1. Company market share
  • Top 5 companies
5.2. Company overview - GlaxoSmithKline
  • Company snapshot
  • Product offerings
  • Growth strategies
  • Initiatives
  • Geographical presence
5.2(A) Executive profile – GlaxoSmithKline
5.3. Company overview – Pfizer Inc.
  • Company snapshot
  • Product offerings
  • Growth strategies
  • Initiatives
  • Geographical presence
5.3(A) Executive profile - Pfizer Inc.
5.4. Company overview – Merck & Co.
  • Company snapshot
  • Product offerings
  • Growth strategies
  • Initiatives
  • Geographical presence
5.4(A) Executive profile - Merck & Co.
5.5. Company overview – Novartis
  • Company snapshot
  • Product offerings
  • Growth strategies
  • Initiatives
  • Geographical presence
5.5(A) Executive profile - Novartis
5.6. Company overview – Sanofi Pasteur
  • Company snapshot
  • Product offerings
  • Growth strategies
  • Initiatives
  • Geographical presence
5.6(A) Executive profile - Sanofi Pasteur
5.7. Company overview – CSL Limited
  • Company snapshot
  • Product offerings
  • Growth strategies
  • Initiatives
  • Geographical presence
5.7(A) Executive profile - CSL Limited

Appendix
  • List of Tables
  • Assumptions
  • Conclusion
  • Research methodology
  • About the publisher
Disclaimer: The Table of Contents (ToC) provided above contains the targeted coverage. The coverage is subject to change as we progress with the research
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • GlaxoSmithKline
  • Pfizer Inc.
  • Merck & Co.
  • Novartis
  • Sanofi Pasteur
  • CSL Limited
  • Bharat Biotech
  • Biological E. Limited
  • Serum Institute of China
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll